ABCL ▼ -5.7% - AbCellera Biologics Inc. $ABCL AbCellera: To Present Phase 1/2 ABCL635 Data at TMS 2026 on Oct. 22 ? • Presentation will include safety, pharmacokinetics, pharmacodynamics and preliminary efficacy data. • New safety data from the Phase 1 multiple ascending dose study and new patient-reported outcomes from Phase 2 will be included. • ABCL635 is a long-acting, non-hormonal NK3R antibody being developed for moderate-to-severe menopausal vasomotor symptoms. 08-OCT-2026 04:14 PM ET